Fig. 7: Rh-chemerin suppressed apoptosis via the chemR23/CAMKK2/AMPK signaling pathway at 24 h post HIE. | Cell Death & Disease

Fig. 7: Rh-chemerin suppressed apoptosis via the chemR23/CAMKK2/AMPK signaling pathway at 24 h post HIE.

From: RETRACTED ARTICLE: Chemerin reverses neurological impairments and ameliorates neuronal apoptosis through ChemR23/CAMKK2/AMPK pathway in neonatal hypoxic–ischemic encephalopathy

Fig. 7

Effects of specific inhibiting chemerin receptor 23 (chemR23), Ca2 + /calmodulin-dependent protein kinase 2 (CAMKK2) and adenosine monophosphate-activated protein kinase (AMPK) with human recombinant chemerin (rh-chemerin) administration on infarct volume (a, b) and body weight (c) at 24 h post hypoxic–ischemic encephalopathy (HIE). a, b The infarct volume was significantly increased in all 4 intervention groups with chemR23 small interfering RNA (siRNA), Alpha-NETA, STO-609, and Dorsomorphin when compared with rh-chemerin+Scramble siRNA or rh-chemerin+DMSO group. Alpha-NETA 2-(α-Naphthoyl)ethyl­tri­methyl­ammonium iodide, STO-609 7-Oxo-7H-benzimidazo[2,1-a]benz[de]isoquinoline-3-carboxylic acid, acetate salt. c rh-chemerin significantly preserved body weight when compared with vehicle; however, all 4 intervention groups with chemR23 siRNA, Alpha-NETA, STO-609, and Dorsomorphin showed to significantly reverse those effects when compared with rh-chemerin+Scramble siRNA or rh-chemerin+DMSO group; *p < 0.05 vs sham, #p < 0.05 vs HIE+vehicle, &p < 0.05 vs HIE+rh-chemerin+Scramble siRNA, @p < 0.05 vs HIE+rh-chemerin+DMSO, n = 6/group. Data are mean ± SD. Analysis of variance (ANOVA), Tukey

Back to article page